Leon Smith
About Leon Smith
Leon Smith is a Principal Scientist at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in developing small molecules for Oncology and Cardiovascular Disease, holding over 40 patents and publications.
Title and Current Position at Bristol Myers Squibb
Leon Smith holds the title of Principal Scientist at Bristol Myers Squibb, a prominent pharmaceutical company. He operates out of Princeton, New Jersey, contributing his extensive experience in drug discovery and development to the company's innovative projects.
Professional Experience at ImClone Systems
Leon Smith worked as Scientist III at ImClone Systems, a subsidiary of Eli Lilly and Company, from 2001 to 2005. During his 4-year tenure in the Greater New York City Area, he engaged in significant research and development work, contributing to ImClone's portfolio of innovative cancer treatments.
Career History at Amgen
Before his tenure at ImClone Systems, Leon Smith served as an Associate Scientist at Amgen from 1996 to 2001. Based in Thousand Oaks, CA, he spent 5 years enhancing his expertise in drug development, focusing particularly on biopharmaceutical research and development.
Educational Background in Chemistry and Biology
Leon Smith earned a Master’s degree in Organic Chemistry from Tennessee State University, studying there from 1994 to 1996. Prior to that, he completed his undergraduate education at Clark Atlanta University, achieving a Bachelor of Science in Biology with a concentration in Biochemistry from 1989 to 1993.
Contributions to Oncology and Cardiovascular Disease Research
Leon Smith has made critical contributions to the development of small molecules that have progressed to human Phase I-III studies, particularly in Oncology and Cardiovascular Disease. His research has led to over 40 patents and peer-reviewed journal publications, focusing on the development of novel small molecule cardiovascular therapeutics with good oral bioavailability and anti-thrombotic potency.